2015 Prescription Drug Prices Jump Another 3.8% in Q1, According to Truveris National Drug IndexSM
Branded Medications Jump 5.7%; Specialty Drugs Rise 2.5%; Generics Up 1.4%
Analyzed by category, branded drug prices jumped 5.7%, specialty drugs rose 2.5% and generic drugs increased 1.4% between January and
The index also points to infertility (12.2%), menopause (8.8%) and hormone deficiency (8.5%) as conditions that saw the highest drug price increases, taking into account composite calculations of brand, specialty and generic medications. Generic drugs for menopause notably spiked 11.1%, increasing at a higher rate than the composite calculation.
“Prescription drug prices continue to rise at a rate that makes it increasingly difficult for businesses to keep the costs of employee benefits in check,” said
The Truveris National Drug Index (NDI) is the only prescription drug price index in the U.S. measuring the average price of prescription drugs, driven by the most commonly utilized prescriptions. Calculated monthly, it provides a holistic, accurate measurement of the prices paid by private insurers, self-insured organizations, government, unions and uninsured patients.
The current index shows:
Truveris NDI Composite
- Between January and
March 2015 , the NDI composite index increased 22.52 points or 3.8%. - For the month of March, the Truveris NDI rose 1.78 points or 0.29%.
Truveris NDI Brand
- Between January and
March 2015 , the brand index increased 17.39 points or 5.7%. - For the month of March, the Truveris NDI Brand rose 1.00 points or 0.31%.
Truveris NDI Generic
- Between January and
March 2015 , the generic index increased 2.1 points or 1.4%. - For the month of March, the Truveris NDI Generic rose 0.21 points or 0.14%.
Truveris NDI Specialty
- Between January and
March 2015 , the specialty index increased 3.49 points or 2.5%. - For the month of March, the Truveris NDI Specialty rose 0.58 points or 0.41%.
About Truveris
Truveris is the leading prescription drug analytics company, on a mission to democratize data and access through technology. Our proprietary Software-as-a-Service platforms drive transparency and lower costs across the pharmacy benefit ecosystem: solutions including RxChoice®, TruBid® and RxDashSM enable clients to select a pharmacy benefit vendor and anticipate financial trends and projected annual spend with unprecedented accuracy and efficiency. Truveris is backed by
© 2015
All trademarks indicated above are owned by Truveris.
For Truveris
Source: Truveris
Royce Williams Announces Promotion of Emma Williams to Sales Agent
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News